Re-positioning of FDA-Approved Compounds in MPS III Cell Models

Cure Sanfilippo Foundation is funding search to explore re-positioning FDA-approved compounds using cell-based, high-content screening in Sanfilippo Syndrome (MPS III) cell models. 

Awardee: Diego Medina, PhD- Telethon Institute of Genetics and Medicine (TIGEM)- Italy 

Start Date: June 2018

UPDATE: October 2019

In October 2019, TIGEM presented preliminary results of this study at the Conference of Telethon Fundamental Associations in Italy. Read more

Bottom of poster presentation at Telethon scientific meeting Oct 2019 about re-positioning FDA-approved compounds for MPS III

Top of poster presentation at Telethon scientific meeting Oct 2019 about re-positioning FDA-approved compounds for MPS III

Cure Sanfilippo Foundation

501c3 non-profit
(Tax ID: 46-4322131)

curesff@gmail.com

P.O. Box 6901
Columbia, SC 29260

N